MétaCan
Menu
Back to cohort
Record W4409833020 · doi:10.1016/j.euo.2025.03.011

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy

2025· article· en· W4409833020 on OpenAlexafffund
Wee Loon Ong, Harvey Quon, Aldrich Ong, Patrick Cheung, William Chu, Hans T. Chung, Danny Vesprini, Amit Chowdhury, Dilip Panjwani, Yasir Alayed, Geordi Pang, Renée Korol, Melanie Davidson, Ananth Ravi, Boyd McCurdy, Liying Zhang, Meghan Kulasingham-Poon, Alexandre Mamedov, Andrea Deabreu, Andrew Loblaw

Bibliographic record

VenueEuropean Urology Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Diagnosis and Treatment
Canadian institutionsHealth Sciences CentreUniversity of TorontoBC Cancer AgencyCancerCare ManitobaSunnybrook Health Science Centre
FundersProstate Cancer Canada
KeywordsMedicineAblative caseProstateRadiosurgeryRadiation therapyTerm (time)OncologyMedical physicsInternal medicineRadiologyCancer

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVE: The PATRIOT multicentre phase 2 trial showed that prolongation of overall treatment time (OTT) for prostate stereotactic ablative body radiotherapy (SABR) was associated with better acute bowel and urinary quality of life. However, the impact on long-term cancer outcomes is unclear. METHODS: Men with favourable-risk localised prostate cancer in the PATRIOT trial were randomised to five-fraction prostate SABR every other day (EOD; n = 77) or once weekly (QW; n = 75).The cancer outcomes evaluated in this post hoc analyses were biochemical failure (BF), metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), and overall survival (OS). KEY FINDINGS AND LIMITATIONS: Median follow-up was 91 mo. The 8-yr cumulative incidence rates for BF were 5.5% in the EOD arm versus 9.6% the QW arm (p = 0.2). The 8-yr probability rates were 100% versus 95.9% for MFS (p = 0.08), 100% versus 97.2% for PCSS (p = 0.2), and 96.0% versus 85.4% for OS (p = 0.3) for the EOD versus QW arms, respectively. The study is limited by the small sample size (powered to detect significant differences in acute bowel quality of life). CONCLUSIONS: This study suggests no significant differences in long-term cancer outcomes between EOD and QW schedules for five-fraction prostate SABR. This trial is registered on ClinicalTrials.gov as NCT01423474.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.004
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.043
GPT teacher head0.382
Teacher spread0.340 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueEuropean Urology OncologySame topicProstate Cancer Diagnosis and TreatmentFrench-language works237,207